Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol,Vitamin E
Therapeutic Area : Sleep
Study Phase : Phase III
Sponsor : Sandoz B2B
Deal Size : $19.0 million
Deal Type : Licensing Agreement
Avecho, Sandoz Sign Exclusive Deal to Commercialize CBD for Insomnia in AUS
Details : Under the agreement, Sandoz gains the commercial rights to Avecho's Phase III cannabidiol (CBD) capsule for insomnia in Australia.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : $3.0 million
March 03, 2025
Lead Product(s) : Cannabidiol,Vitamin E
Therapeutic Area : Sleep
Highest Development Status : Phase III
Sponsor : Sandoz B2B
Deal Size : $19.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Testosterone Undecanoate,Vitamin E
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipocine Announces Positive LPCN 2401 Results Showing Improved Body Composition
Details : LPCN 2401, an oral proprietary combination of anabolic androgen receptor agonist (Testosterone Undecanoate) and α-tocopherol, an antioxidant, is being investigated for the treament of obesity.
Product Name : Tlando
Product Type : Hormone
Upfront Cash : Inapplicable
November 04, 2024
Lead Product(s) : Testosterone Undecanoate,Vitamin E
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pentoxifylline,Vitamin E
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2024
Lead Product(s) : Pentoxifylline,Vitamin E
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Kojic Acid,Vitamin E,Vitamin A
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : Menarini
Deal Size : Inapplicable
Deal Type : Inapplicable
Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 18, 2023
Lead Product(s) : Kojic Acid,Vitamin E,Vitamin A
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : Menarini
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coenzyme Q10,Vitamin E
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Sanofi Completes Acquisition of Qunol®
Details : Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the US.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Undisclosed
September 29, 2023
Lead Product(s) : Coenzyme Q10,Vitamin E
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Pentoxifylline,Vitamin E,Clodronic Acid Disodium Salt
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 26, 2023
Lead Product(s) : Pentoxifylline,Vitamin E,Clodronic Acid Disodium Salt
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coenzyme Q10,Vitamin E
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Sanofi to Acquire Qunol®, a Fast-Growing U.S. Brand in the Healthy Aging Segment
Details : Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the U.S.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Undisclosed
July 27, 2023
Lead Product(s) : Coenzyme Q10,Vitamin E
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Astaxanthin Grape Extract,Vitamin E
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Clinical Research Australia
Deal Size : Inapplicable
Deal Type : Inapplicable
Nutritional Supplement's Effects on Cognition
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
July 12, 2023
Lead Product(s) : Astaxanthin Grape Extract,Vitamin E
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Clinical Research Australia
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tocotrienol,Vitamin E
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Monash University Malaysia | Hovid BHD
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 11, 2021
Lead Product(s) : Tocotrienol,Vitamin E
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Monash University Malaysia | Hovid BHD
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vitamin E,Omega-3
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Royal DSM
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
December 13, 2019
Lead Product(s) : Vitamin E,Omega-3
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Royal DSM
Deal Size : Inapplicable
Deal Type : Inapplicable